A Powerful Natural Antioxidant for Health and Beauty
Home  References  Alpha Lipoic Acid References - Section III

Alpha Lipoic Acid References - Section III

  1. Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?. Seybolt, Sheila E.J. [ed.] Mehar S. Manku. 6, Birmingham: Elsevier Ltd., December 2010, Medical Hypotheses, Vol. 75, pp. 572-575. DOI: 10.1016/j.mehy.2010.07.034; http://www.medical-hypotheses.com/article/S0306-9877(10)00272-0/abstract. ISSN: 0306-9877.
  2. Alpha-lipoic acid as a dietary supplement: Molecular mechanisms and therapeutic potential. Shay, Kate Petersen, et al., et al. [ed.] E. Arnér and S.S. Krag. 10, Stockholm; Baltimore: Elsevier B.V., October 2009, Biochimica et Biophysica Acta (BBA) — General Subjects, Vol. 1790, pp. 1149-1160. DOI: 10.1016/j.bbagen.2009.07.026; http://www.sciencedirect.com/science/article/pii/S0304416509002153. ISSN: 0304-4165.
  3. Treatments for mitochondrial dysfunction associated with autism spectrum disorders. Frye, Richard E. and Rossignol, Daniel A. [ed.] Hüseyin Çaksen and Mustafa Cemek. 4, Konya; Istanbul: IOS Press: Society of Child Science, Yüzüncü Yıl University, Faculty of Medicine, December 14, 2012, Journal of Pediatric Biochemistry, Vol. 2, pp. 241-249. DOI: 10.3233/JPB-120065http://content.iospress.com/articles/journal-of-pediatric-biochemistry/jpb00065. ISSN: 1879-5390.
  4. Effects of alpha-lipoic acid in an animal model of mania induced by d-amphetamine. Macêdo, Danielle S., et al., et al. [ed.] K.N. Roy Chengappa and Samuel Gershon. 7, Pittsburgh: John Wiley and Sons A/S, November 2012, Bipolar Disorders, Vol. 14, pp. 707-718. DOI: 10.1111/j.1399-5618.2012.01046.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1399-5618.2012.01046.x/abstract. eISSN: 1399-5618.
  5. A Placebo-Controlled Trial of Acetyl-l-Carnitine and α-Lipoic Acid in the Treatment of Bipolar Depression. Brennan, Brian P., et al., et al. [ed.] Richard I. Shader and David J. Greenblatt. 5, Medford: Lippincott Williams & Wilkins, Inc., October 2013, Journal of Clinical Psychopharmacology, Vol. 33, pp. 627-635. DOI: 10.1097/JCP.0b013e31829a83f5; http://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=2013&issue=10000&article=00007&type=abstract. ISSN: 0271-0749.
  6. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: A randomized, double-blind, placebo controlled trial. López-D'alessandro, Edgardo and Escovich, Livia. [ed.] Jose V. Bagan and Crispian Scully. 5, Valencia; London: Sociedad Española de Medicina Oral, Sociedad Española de Odontoestomatología para el Minusválido y Pacientes Especiales, Sociedad Española de Cirugía Bucal, Academia Iberoamericana de Patología y Medicinal Bucal, August 1, 2011, Medicina Oral Patologia Oral y Cirugia Bucal, Vol. 16, pp. e635-640. DOI: 10.4317/medoral.16942; http://www.medicinaoral.com/pubmed/medoralv16_i5_p635.pdf. ISSN: 1698-4447.
  7. Treatment of carpal tunnel syndrome with alpha-lipoic acid. Di Geronimo, G., et al., et al. [ed.] Aldo V. Greco and Antonio Gasbarrini. 2, Rome: Verduci Editore s.r.l., March-April 2009, European Review for Medical and Pharmacological Sciences, Vol. 13, pp. 133-139. ISSN: 1128-3602.
  8. Effect of Combined Administration of Alpha Lipoic Acid and Sertraline on Clinical Global Impression (CGI) Score in Depressive Patients. Manmohan, Tepoju, Sreenivas, Chakravarthy K.G. and K., Sarath Babu. [ed.] Varaprasad Bobbarala. 12, Andhrapradesh: s.n., 2013, International Journal of Bioassays, Vol. 2, pp. 1580-1582. ISSN: 2278-778X.
  9. Idiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapy. Femiano, F., Scully, C. and Gombos, F. [ed.] Piet Haers. 6, Guildford: Elsevier Ltd., December 2002, International Journal of Oral and Maxillofacial Surgery, Vol. 31, pp. 625-628. DOI: 10.1054/ijom.2002.0276; http://www.ijoms.com/article/S0901-5027(02)90276-6/abstract. ISSN: 0901-5027.
  10. The Effect of Alpha-Lipoic Acid on Learning and Memory Deficit in a Rat Model of Temporal Lobe Epilepsy. Baluchnejadmojarad, Tourandokht, et al., et al. [ed.] Mohammad Taghi Joghataei. 3, Tehran: Tehran University of Medical Sciences, Spring 2012, Basic and Clinical Neuroscience, Vol. 3, pp. 58-66. eISSN: 2228-7442.
  11. Balch, James and Stengler, Mark. Prescription for Natural Cures: A Self-Care Guide for Treating Health Problems with Natural Remedies Including Diet and Nutrition, Nutritional Supplements, Bodywork, and More. Hoboken: John Wiley & Sons, Inc., 2004. ISBN: 0-471-49088-1.
  12. The effect of alpha-lipoic acid on temporary threshold shift in humans: a preliminary study. Quaranta, N., et al., et al. [ed.] Gaetano Paludetti. 6, Rome: Società Italiana di Otorinolaringologia e Chirurgia Cervico-Facciale, December 2012, ACTA Otorhinolaryngologica Italica, Vol. 32, pp. 380-385. PMCID: PMC3552536. ISSN: 0392-100X.
  13. Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling. Packer, Lester and Cadenas, Enrique. [ed.] Toshikazu Yoshikawa. 1, Kyoto: Society for Free Radical Research Japan, January 2011, Journal of Clinical Biochemistry and Nutrition, Vol. 48, pp. 26-32. DOI: 10.3164/jcbn.11-005FR; https://www.jstage.jst.go.jp/article/jcbn/48/1/48_11-005FR/_article. ISSN: 0912-0009.
  14. Lipoic Acid in the Treatment of Smell Dysfunction Following Viral Infection of the Upper Respiratory Tract. Hummel, Thomas, Heilmann, Stefan and Huttenbriuk, Karl-Bernd. [ed.] Byron J. Bailey. 11, Omaha: John Wiley & Sons, Inc.: The Triological Society, November 2002, The Laryngoscope, Vol. 112, pp. 2076-2080. DOI: 10.1097/00005537-200211000-00031; http://onlinelibrary.wiley.com/doi/10.1097/00005537-200211000-00031/abstract. ISSN: 0023-852X.
  15. Yadav, Vijayshree, Marracci, Gail and Bourdette, Dennis N. Lipoic Acid — A Novel Therapeutic Approach for Multiple Sclerosis. Department of Neurology, Oregon Health and Science University. s.l.: Touch Briefings, 2008. pp. 12-15, Projects in Knowledge. DOI: 10.17925/USN.2008.04.02.12; http://www.touchneurology.com/articles/lipoic-acid-novel-therapeutic-approach-multiple-sclerosis-0.
  16. New Developments in the Prevention and Treatment of Neurodegenerative Diseases Using Nutraceuticals and Metabolic Stimulants. Blaylock, Russell L. 1, Birmingham: American Nutraceutical Association, Winter 2002, Journal of the American Nutraceutical Association, Vol. 5, pp. 15-32. ISSN: 1521-4524.
  17. Management of the aging risk factor for Parkinson's disease. Phillipson, Oliver T. [ed.] Paul D. Coleman. 4, Rochester: Elsevier, April 2014, Neurobiology of Aging, Vol. 35, pp. 847-857. DOI: 10.1016/j.neurobiolaging.2013.10.073; http://www.neurobiologyofaging.org/article/S0197-4580(13)00525-3/abstract. ISSN: 0197-4580.
  18. The Biochemical and Cellular Basis for Nutraceutical Strategies to Attenuate Neurodegeneration in Parkinson's Disease. Mazzio, Elizabeth A., Close, Fran and Soliman, Karam F.A. [ed.] Andrei Alexandrescu. 1, Storrs: MDPI AG, January 17, 2011, International Journal of Molecular Sciences, Vol. 12, pp. 506-569. DOI: 10.3390/ijms12010506; http://www.mdpi.com/1422-0067/12/1/506. ISSN: 1422-0067.
  19. Pai, Sunil. Peripheral Neuropathy. [ed.] David Rakel. Integrative Medicine. 3. Philadelphia: Saunders: Elsevier Science, 2012, 11, pp. 102-113.e5. ISBN: 978-1-4377-1793-8.
  20. Thioctic Acid and Acetyl-L-Carnitine in the Treatment of Sciatic Pain Caused by a Herniated Disc. Memeo, Antonio and Loiero, Mario. [ed.] Jasbir Singh. 8, Auckland: Springer International Publishing, August 2008, Clinical Drug Investigation, Vol. 28, pp. 495-500. DOI: 10.2165/00044011-200828080-00004; http://link.springer.com/article/10.2165%2F00044011-200828080-00004. ISSN: 1173-2563.
  21. Lipoic acid protects against reperfusion injury in the early stages of cerebral ischemia. Connell, Barry J., et al., et al. [ed.] Irwin B. Levitan. Philadelphia: Elsevier B.V., February 23, 2011, Brain Research, Vol. 1375, pp. 128-136. DOI: 10.1016/j.brainres.2010.12.045; http://www.sciencedirect.com/science/article/pii/S0006899310027101. ISSN: 0006-8993.
  22. Co-Administration of Resveratrol and Lipoic Acid, or Their Synthetic Combination, Enhances Neuroprotection in a Rat Model of Ischemia/Reperfusion. Saleh, Monique C., et al., et al. [ed.] Vardan Karamyan. 1, Amarillo: Public Library of Science, January 31, 2014, PLoS ONE, Vol. 9, p. e87865. DOI: 10.1371/journal.pone.0087865; http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087865. ISSN: 1932-6203.
  23. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial. Khalili, Mohammad, et al., et al. [ed.] Chandan Prasad. 1, Denton: W.S. Maney & Son Ltd, January 2014, Nutritional Neuroscience, Vol. 17, pp. 16-20. DOI: 10.1179/1476830513Y.0000000060; http://www.maneyonline.com/doi/abs/10.1179/1476830513Y.0000000060. ISSN: 1028-415X.
  24. Prasad, Kedar N. Intervention with Multiple Micronutrients Including Dietary and Endogenous Antioxidants for Healthy Aging. [ed.] Stephen Bondy and Kenneth Maiese. Aging and Age-Related Disorders. New York: Springer Science+Business Media, LLC: Humana Press, 2010, Vols. Oxidative Stress in Applied Basic Research and Clinical Practice, Volume 3, pp. 55-78. ISBN: 978-1-60761-601-6.
  25. Head, Elizabeth. Antioxidants Combined with Behavioral Enrichment Can Slow Brain Aging. [ed.] Stephen Bondy and Kenneth Maiese. Aging and Age-Related Disorders. New York: Springer Science+Business Media, LLC: Humana Press, 2010, Vols. Oxidative Stress in Applied Basic Research and Clinical Practice, Volume 3. ISBN: 978-1-60761-601-6.
  26. Marshall, Robert J. The Overlooked Role of Chronic Infection in Neurodegeneration and Its Reversal Using Nutraceutical Agents. Winter Park: Heise Health Clinic, 2005. pp. 1-23.
  27. Dairam, Amichaud. An Investigation into the Neuroprotective Properties of the Non-Steroidal Anti-Inflammatory Agents Tolmetin, Sulindac and Turmeric. Pharmacy. Grahamstown: Rhodes University, 2006. Thesis.
  28. Oxidative Stress and Epilepsy: Literature Review. Torres Aguiar, Carlos Clayton, et al., et al. [ed.] Regina Menezes. Article ID 795259, Oeiras: Hindawi Publishing Corporation, May 24, 2012, Oxidative Medicine and Cellular Longevity, Vol. 2012, pp. 1-12. DOI: 10.1155/2012/795259; http://www.hindawi.com/journals/omcl/2012/795259/. ISSN: 1942-0900.
  29. The molecular basis of neurodegeneration in multiple sclerosis. Lassmann, Hans and van Horssen, Jack. [ed.] Felix Wieland. 23, Heidelberg: Elsevier B.V., December 1, 2011, FEBS Letters, Vol. 585, pp. 3715-3723. DOI: 10.1016/j.febslet.2011.08.004; http://www.febsletters.org/article/S0014-5793(11)00593-X/abstract. ISSN: 0014-5793.
  30. P.248: Role of Alpha-Lipoic Acid in Improvement of Paclitaxel/Carboplatin Induced Neuropathy in Metastatic Breast Cancer: An Egyption Experience. Ghali, R.R., Basiuony, M. EL. and Elleithy, M.A. [ed.] W. K. Alfred Yung. suppl 3, Marseille: Oxford University Press: Society for Neuro-Oncology, September 6-9, 2012, Abstracts from the 10th Congress of European Association Of Neuro-Oncology, Vol. 14, pp. iii1-iii94. DOI: 10.1093/neuonc/nos183; http://neuro-oncology.oxfordjournals.org/content/14/suppl_3/iii1. ISSN: 1522-8517.
  31. Gallagher, Catherine, Rindfleisch, J. Adam and Podein, Rian. Parkinson's Disease. [ed.] David Rakel. Integrative Medicine. 2nd. Philadelphia: Saunders: Elsevier Inc., 2007, 17, pp. 177-186. ISBN: 978-1-4160-2954-0.
  32. The Natural Killer Cell: A Historical Perspective and the Use of Supplements to Enhance NKC Activity. Thornthwaite, Jerry T., et al., et al. [ed.] Ronald B. Moss. 3, Irvine: Scientific Research Publishing Inc., October 25, 2012, Journal of Immune Based Therapies, Vaccines and Antimicrobials, Vol. 1, pp. 21-51. DOI: 10.4236/jibtva.2012.13004; http://www.scirp.org/journal/PaperDownload.aspx?DOI=10.4236/jibtva.2012.13004. ISSN: 2168-1546.
  33. Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimer's Disease. de la Monte, Suzanne M. [ed.] Debomoy K. Lahiri. 1, Indianapolis: Bentham Science Publishers, January 2012, Current Alzheimer Research, Vol. 9, pp. 35-66. DOI: 10.2174/156720512799015037; http://www.eurekaselect.com/88685/article. ISSN: 1567-2050.
  34. Maczurek, Annette E., et al., et al. Lipoic Acid as a Novel Treatment for Mild Cognitive Impairment and Early-Stage Alzheimer's Disease. [ed.] Lester Packer, et al., et al. Micronutrients and Brain Health. Boca Raton: CRC Press: Taylor and Francis Group, LLC, 2010, 10, pp. 134-148. ISBN: 978-1-4200-7351-5.
  35. Alpha-lipoic acid effects on brain glial functions accompanying double-stranded RNA antiviral and inflammatory signaling. Scumpia, Philip O., Kelly-Scumpia, Kindra and Stevens, Bruce R. [ed.] Michael B. Robinson. Philadelphia: Elsevier B.V., January 2014, Neurochemistry International, Vol. 64, pp. 55-63. DOI: 10.1016/j.neuint.2013.11.006; http://www.sciencedirect.com/science/article/pii/S0197018613002970. ISSN: 0197-0186.
  36. The Effect of Lipoic Acid on Cyanate Toxicity in Different Structures of the Rat Brain. Sokołowska, Maria, et al., et al. [ed.] Richard M. Kostrzewa. 3, Johnson City: Springer US, October 2013, Neurotoxicity Research, Vol. 24, pp. 345-357. DOI: 10.1007/s12640-013-9395-2; http://link.springer.com/article/10.1007%2Fs12640-013-9395-2. ISSN: 1029-8428.
  37. Lipoic Acid Increases Hippocampal Choline Acetyltransferase and Acetylcholinesterase Activities and Improvement Memory in Epileptic Rats. de Freitas, Rivelilson Mendes. [ed.] Abel Lajtha. 1, New York: Springer US, January 1, 2010, Neurochemical Research, Vol. 35, pp. 162-170. DOI: 10.1007/s11064-009-0041-6; http://link.springer.com/article/10.1007%2Fs11064-009-0041-6. ISSN: 0364-3190.
  38. Mechanism of alpha-lipoic acid in attenuating kanamycin-induced ototoxicity. Wang, Aimei, et al., et al. [ed.] Kwok-Fai So and Xiao-Ming Xu. 35, Shenyang: Publishing House of Neural Regeneration Research, December 2012, Neural Regeneration Research, Vol. 7, pp. 2793-2800. DOI: 10.3969/j.issn.1673-5374.2012.35.007; http://med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_PM25317129. ISSN: 1673-5374.
  39. Mann, John Douglas and Coeytaux, Remy R. Headache. [ed.] David Rakel. Integrative Medicine. 3. Philadelphia: Saunders: Elsevier Inc., 2012, 10, pp. 91-101.e2. ISBN: 978-1-4377-1793-8.
  40. Prasad, Kedar N. Scientific Rationale of Current Trends in Clinical Studies of Micronutrients for Prevention of Chronic Diseases. Micronutrients in Health and Disease. Boca Raton: CRC Press: Taylor & Francis Group, LLC, 2011, 3, pp. 23-34. ISBN: 978-1-4398-2106-0.
  41. Sturchler, Emmanuel, Feurstein, Daniel and Duckett, Patricia McDonaldl Derek. ASK1 and Its Role in Neurodegenerative Diseases. [ed.] Raymond Chuen-Chung Chang. Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring. Rijeka: InTech, 2011, 9, pp. 217-234. ISBN: 978-953-307-485-6.
  42. Effect of (R)-α-Lipoic Acid Supplementation on Serum Lipids and Antioxidative Ability in Patients with Age-Related Macular Degeneration. Sun, Y.D., et al., et al. [ed.] Berthold Koletzko. 4, Munich: Karger AG, Basel, June 2012, Annals of Nutrition & Metabolism, Vol. 60, pp. 293-297. ISSN: 0250-6807.
  43. Zelefsky, Joseph R. and Ritch, Robert. Alternative and Non-traditional Treatments of Glaucoma. [ed.] Paul N. Schacknow and John R. Samples. The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care. New York Dordrecht Heidelberg London: Springer Science+Business Media, LLC, 2010, 56, pp. 657-669. ISBN: 978-0-387-76699-7.
  44. Henchcliffe, Claire and Beal, M. Flint. Potential Therapies for Mitochondrial Dysfunction. [ed.] Amy Katherine Reeve, et al., et al. Mitochondrial Dysfunction in Neurodegenerative Disorders. London: Springer-Verlag London Limited, 2012, 13, pp. 215-230. ISBN: 978-0-85729-700-6; DOI: 10.1007/978-0-85729-701-3.
  45. Therapeutic perspectives on the combination of α-lipoic acid and vitamin E. Gonzalez-Perez, Oscar and Gonzalez-Castaneda, Rocio E. [ed.] Bruce A. Watkins. 1, New York: Elsevier Inc., January 1, 2006, Nutrition Research, Vol. 26, pp. 1-5. DOI: 10.1016/j.nutres.2005.11.011; http://www.nrjournal.com/article/S0271-5317(05)00281-2/abstract. ISSN: 0271-5317.
  46. Experimental Study of the Neuroprotective Properties of Alpha-Lipoic Acid and Superoxide Dismutase in Cerebral Ischemia in Rats. Shmonin, A.A., et al., et al. [ed.] Charles D. Woody. 5, Los Angeles: Springer US, June 2012, Neuroscience and Behavioral Physiology, Vol. 42, pp. 429-433. DOI: 10.1007/s11055-012-9583-1; http://link.springer.com/article/10.1007%2Fs11055-012-9583-1. ISSN: 0097-0549.
  47. A Preliminary Investigation of [alpha]-Lipoic Acid Treatment of Antipsychotic Drug-Induced Weight Gain in Patients With Schizophrenia. Kim, Eosu, et al., et al. [ed.] Richard I. Shader and David J. Greenblatt. 2, Medford: Lippincott Williams & Wilkins, Inc., April 2008, Journal of Clinical Psychopharmacology, Vol. 28, pp. 138-146. DOI: 10.1097/JCP.0b013e31816777f7; http://journals.lww.com/psychopharmacology/pages/articleviewer.aspx?year=2008&issue=04000&article=00003&type=abstract. ISSN: 0271-0749.
  48. A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer's Disease. Shinto, Lynne, et al., et al. [ed.] George Perry. 1, San Antonio: IOS Press, January 2014, Journal of Alzheimer's Disease, Vol. 38, pp. 111-120. DOI: 10.3233/JAD-130722; http://content.iospress.com/articles/journal-of-alzheimers-disease/jad130722. ISSN: 1387-2877.
  49. Brain foods: the effects of nutrients on brain function. Gómez-Pinilla, Fernando. [ed.] Claudia Wiedemann. 7, London: Macmillan Publishers Limited: Nature Publishing Group, July 2008, Nature Reviews Neuroscience, Vol. 9, pp. 568-578. DOI: 10.1038/nrn2421; http://www.nature.com/nrn/journal/v9/n7/full/nrn2421.html. ISSN: 1471-003X.
  50. A Randomized Double-Blind Placebo-Controlled Trial of Thioctic Acid in Migraine Prophylaxis. Magis, Delphine, et al., et al. [ed.] Thomas N. Ward. 1, s.l.: John Wiley & Sons, Inc., January 2007, Headache: The Journal of Head and Face Pain, Vol. 47, pp. 52-57. DOI: 10.1111/j.1526-4610.2006.00626.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2006.00626.x/abstract. ISSN: 1526-4610.
  51. Pierce, Surya and Ammon, Patricia. Multiple Sclerosis. [ed.] David Rakel. Integrative Medicine. 3rd. Philadelphia: Saunders: Elsevier Inc., 2012, 12, pp. 114-121.e2. ISBN: 978-1-4377-1793-8.
  52. Reactive astrocytes as therapeutic targets for CNS disorders. Hamby, Mary E. and Sofroniew, Michael V. [ed.] Alan I. Faden. 4, Baltimore: Elsevier, October 1, 2010, Neurotherapeutics, Vol. 7, pp. 494-506. DOI: 10.1016/j.nurt.2010.07.003; http://link.springer.com/article/10.1016%2Fj.nurt.2010.07.003. ISSN: 1933-7213.
  53. Molecular mechanisms for anti-aging by natural dietary compounds. Pan, Min-Hsiung, et al., et al. [ed.] Hans-Ulrich Humpf. 1, Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, January 2012, Molecular Nutrition & Food Research, Vol. 56, pp. 88-115. DOI: 10.1002/mnfr.201100509; http://onlinelibrary.wiley.com/doi/10.1002/mnfr.201100509/abstract. ISSN: 1613-4133.
  54. Freye, Enno. Representative Ailments with Excess Nitric Oxide Formation. Acquired Mitochondropathy - A New Paradigm in Western Medicine Explaining Chronic Diseases. Dordrecht: Springer Science+Business Media, 2012, 5, pp. 37-54. ISBN: 978-94-007-2035-0.
  55. Sun, Albert Y., et al., et al. Botanical Phenolics and Neurodegeneration. [ed.] Iris F.F. Benzie and Sissi Wachtel-Galor. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd. Boca Raton: CRC Press: Taylor & Francis Group, LLC, 2011, Vol. 28 of Oxidative Stress and Disease, 15, pp. 315-332. ISBN: 978-1-4398-0713-2.
  56. Ramiro-Puig, Emma, et al., et al. Food Antioxidants and Alzheimer's Disease. [ed.] Lester Packer, et al., et al. Micronutrients and Brain Health. Boca Raton: CRC Press: Taylor and Francis Group, LLC, 2010, 4, pp. 41-50. ISBN: 978-1-4200-7351-5.
  57. Bailey, Sarah J. and McCaffery, Peter J. Vulnerability of the Brain to Neuropsychiatric Disorders. [ed.] Michael S. Ritsner. Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Dordrecht: Springer Science+Business Media B.V., 2010, 5, pp. 105-134. ISBN: 978-90-481-8552-8.
  58. Ehrlich, Steven D. Dementia. University of Maryland Medical Center. [Online] March 14, 2014. [Cited: December 14, 2015.] http://umm.edu/health/medical/altmed/condition/dementia.
  59. Development of Tau Aggregation Inhibitors for Alzheimer's Disease. Bulic, Bruno, et al., et al. [ed.] Peter Gölitz. 10, Weinheim: Wiley-VCH Verlag GmbH & Co., February 2, 2009, Angewandte Chemie International Edition, Vol. 48, pp. 1740-1752. DOI: 10.1002/anie.200802621; http://onlinelibrary.wiley.com/doi/10.1002/anie.200802621/abstract. eISSN: 1521-3773.
  60. Immune blood biomarkers of Alzheimer disease patients. Avagyan, Hripsime, et al., et al. [ed.] Cedric S. Raine. 1-2, Bronx: Elsevier Inc., May 29, 2009, Journal of Neuroimmunology, Vol. 210, pp. 67-72. DOI: 10.1016/j.jneuroim.2009.02.015; http://www.jni-journal.com/article/S0165-5728(09)00067-8/abstract. ISSN: 0165-5728.
  61. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Gomes, Marilia Brito and Negrato, Carlos Antonio. [ed.] Daniel Giannella-Neto. 80, São Paulo: BioMed Central, December 2014, Diabetology & Metabolic Syndrome, Vol. 6, pp. 1-18. DOI: 10.1186/1758-5996-6-80; http://www.dmsjournal.com/content/6/1/80. eISSN: 1758-5996.
  62. Alzheimer's Disease: The Pros and Cons of Pharmaceutical, Nutritional, Botanical, and Stimulatory Therapies, with a Discussion of Treatment Strategies from the Perspective of Patients and Practitioners. Wollen, Keith A. [ed.] Kathleen A. Head. 3, Napa: Thorne Research, Inc., September 2010, Alternative Medicine Review, Vol. 15, pp. 223-244. ISSN: 1089-5159.
  63. Down Syndrome and Dementia: A Randomized, Controlled Trial of Antioxidant Supplementation. Lott, Ira T., et al., et al. [ed.] John C. Carey. 8, Salt Lake City: Wiley-Liss, Inc., August 2011, American Journal of Medical Genetics, Vol. 155A, pp. 1938-1948. DOI: 10.1002/ajmg.a.34114; http://onlinelibrary.wiley.com/doi/10.1002/ajmg.a.34114/abstract. eISSN: 1552-4833.
  64. Frontier of Epilepsy Research - mTOR signaling pathway. Cho, Chang-Hoon. [ed.] Dae-Myung Jue. 5, Seoul: Nature Publishing Group; Korean Society for Biochemistry and Molecular Biology, May 31, 2011, Experimental & Molecular Medicine, Vol. 43, pp. 231-274. DOI: 10.3858/emm.2011.43.5.032; http://www.nature.com/emm/journal/v43/n5/full/emm201128a.html. eISSN: 2092-6413.
  65. Protective Effect of Curcumin in behavioral impairment induced by Pentylenetetrazol in rats. Sharma, Vandana, et al., et al. [ed.] S. Parial. 1, Bangalore: Informatics India Ltd., January 2011, Journal of Pharmacy Research, Vol. 4, pp. 11-14. ISSN: 0974-6943.
  66. Shpakov, Alexander, et al., et al. Hormonal Signaling Systems of the Brain in Diabetes Mellitus. [ed.] Raymond Chuen-Chung Chang. Neurodegenerative Diseases - Processes, Prevention, Protection and Monitoring. Hong Kong: InTech, 2011, 15, pp. 349-386. ISBN: 978-953-307-485-6.
  67. Evaluation of the antiepileptic effect of curcumin and Nigella sativa oil in the pilocarpine model of epilepsy in comparison with valproate. Noor, Neveen A., et al., et al. [ed.] Steven C. Schachter. 2, Boston: Elsevier Inc., June 2012, Epilepsy & Behavior, Vol. 24, pp. 199-206. DOI: 10.1016/j.yebeh.2012.03.026; http://www.epilepsybehavior.com/article/S1525-5050(12)00171-0/abstract. ISSN: 1525-5050.
  68. Pictorial Review of Glutamate Excitotoxicity: Fundamental Concepts for Neuroimaging. Mark, Leighton P., et al., et al. [ed.] Robert M. Quencer. 3, Miami: American Society of Neuroradiology, Nov-Dec 2001, American Journal of Neuroradiology, Vol. 22, pp. 1813-1824. ISSN: 1936-959X.
  69. Biological Sciences Curriculum Study. The Brain: Understanding Neurobiology Through the Study of Addiction - Neurons, Brain Chemistry, and Neurotransmission. Colorado Springs: U.S. Department of Health and Human Services: National Institutes of Health, 2010. pp. 41-64. NIH Publication No. 09-4871 ISBN: 1-929614-05-5.
  70. National Institutes of Health. National Kidney and Urologic Diseases Information Clearinghouse: Erectile Dysfunction. The National Institute of Diabetes and Digestive and Kidney Diseases. [Online] November 2015. [Cited: November 25, 2015.] http://www.niddk.nih.gov/health-information/health-topics/urologic-disease/erectile-dysfunction/Pages/facts.aspx. NIH Publication No. 09-3923.
  71. May Diet and Dietary Supplements Improve the Wellness of Multiple Sclerosis Patients? A Molecular Approach. Riccio, Paolo, Rossano, Rocco and Liuzzi, GraziaMaria. [ed.] Corrado Betterle. Article ID 249842, Padua: SAGE-Hindawi Access to Research, December 27, 2010, Autoimmune Diseases, Vol. 2010, pp. 1-12. DOI: 10.4061/2010/249842; http://www.hindawi.com/journals/ad/2010/249842/. ISSN: 2090-0430.
  72. Tortora, Gerard J. and Derrickson, Bryan. Nervous Tissue. Principles of Anatomy & Physiology. 13th. Hoboken: John Wiley & Sons, Inc., 2012, 12, pp. 447-491. ISBN-13: 978-0470-56510-0.
  73. Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Khalili, M., et al., et al. [ed.] W. Savino. 6, Rio de Janeiro: Karger AG, Basel, June 2014, NeuroImmunoModulation, Vol. 21, pp. 291-296. DOI: 10.1159/000356145; http://www.karger.com/?doi=10.1159/000356145. ISSN: 1021-7401.
  74. Ammon, Patricia. Multiple Sclerosis. [ed.] David Rakel. Integrative Medicine. Philadelphia: Saunders: Elsevier Science, 2003, 9, pp. 85-92. ISBN: 0-7216-9288-5.
  75. Torkos, Sherry. The Canadian Encyclopedia of Natural Medicine. Mississauga: John Wiley and Sons Canada, Ltd., 2008. ISBN: 978-0-470-83908-9.
  76. Kotsirilos, Vicki, Vitetta, Luis and Sali, Avni. Diabetes. A Guide to Evidence-Based Integrative and Complementary Medicine. Chatswood: Churchill Livingstone: Elsevier Australia, 2011, 13, pp. 328-360. ISBN: 978-0-7295-3908-1.
  77. Update on the management of diabetic polyneuropathies. Shakher, Jayadave and Stevens, Martin J. [ed.] Steven V. Edelman. 4, San Diego: Dove Medical Press Ltd, July 2011, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 2011, pp. 289-305. DOI: 10.2147/DMSO.S11324; https://www.dovepress.com/update-on-the-management-of-diabetic-polyneuropathies-peer-reviewed-article-DMSO. ISSN: 1178-7007.
  78. Putting Evidence Into Practice®: Evidence-Based Interventions for Chemotherapy-Induced Peripheral Neuropathy. Visovsky, Constance, et al., et al. [ed.] Deborah K. Mayer. 6, Pittsburgh: Oncology Nursing Society, December 2007, Clinical Journal of Oncology Nursing, Vol. 11, pp. 901-913. DOI: 10.1188/07.CJON.901-913; https://cjon.ons.org/cjon/11/6/putting-evidence-practice%c2%ae-evidence-basbased-interventions-chemotherapy-induced-peripheral. ISSN: 1092-1095.
  79. Grading of chemotherapy-induced peripheral neuropathy. Postma, T.J. and Heimans, J.J. [ed.] David Kerr. 5, Oxford: Kluwer Academic Publishers: European Society Medical Oncology, May 2000, Annals of Oncology, Vol. 11, pp. 509-513. ISSN: 0923-7534.
  80. Amelioration of docetaxel/cisplatin induced polyneuropathy by α-lipoic acid. Gedlicka, C., et al., et al. [ed.] David Kerr. 2, Oxford: Oxford University Press: European Society Medical Oncology, February 2003, Annals of Oncology, Vol. 14, pp. 339-340. DOI: 10.1093/annonc/mdg051; http://annonc.oxfordjournals.org/content/14/2/339. ISSN: 0923-7534.
  81. Misulis, Karl E. Sensory Abnormalities of the Limbs, Trunk, and Face. [ed.] Walter George Bradley. Neurology in Clinical Practice: Principles of diagnosis and management. 4. Philadelpha: Butterworth Heinemann: Elsevier Inc., 2004, Vol. Volume 1 of Neurology in Clinical Practice, 31, pp. 407-418. ISBN: 9997625889.
  82. Kirchheimer, Sid. Diabetes Health Center: Antioxidant Soothes Diabetic Neuropathy. WebMD Health News. [Online] April 11, 2003. [Cited: November 30, 2015.] http://diabetes.webmd.com/news/20030411/antioxidant-soothes-diabetic-neuropathy.
  83. Pennsylvania State University. Biology 230 - Molecules and Cells: Membrane Potential, Ion Transport and Nerve Impulse. Penn State WikiSpaces. [Online] August 10, 2009. [Cited: December 10, 2015.] https://wikispaces.psu.edu/display/230/Membrane+Potential%2C+Ion+Transport+and+Nerve+Impulse#MembranePotential,IonTransportandNerveImpulse-Theactionpotential.
  84. Marcovitch, Harvey. Black's Medical Dictionary. 41. London: A & C Black Publishers Limited, 2005. ISBN: 0-7136-6146-1.
  85. Monoclonal gammopathy of undetermined significance: a consensus statement. Berenson, James R., et al., et al. [ed.] Finbarr E. Cotter. 1, London: Blackwell Publishing Ltd, July 2010, British Journal of Haematology, Vol. 150, pp. 28-38. DOI: 10.1111/j.1365-2141.2010.08207.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2010.08207.x/abstract. ISSN: 1365-2141.
  86. Alcoholic neuropathy: possible mechanisms and future treatment possibilities. Chopra, Kanwalijit and Tiwari, Vinod. [ed.] James M. Ritter. 3, Oxford: John Wiley & Sons, Inc.: The British Pharmacological Society, March 2012, British Journal of Clinical Pharmacology, Vol. 73, pp. 348-362. DOI: 10.1111/j.1365-2125.2011.04111.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.04111.x/abstract. ISSN: 0306-5251.
  87. The Sensory Symptoms of Diabetic Polyneuropathy Are Improved With α-Lipoic Acid: The SYDNEY Trial. Ametov, Alexander S., et al., et al. [ed.] Mayer B. Davidson. 3, Alexandria: American Diabetes Association, March 2003, Diabetes Care, Vol. 26, pp. 770-776. DOI: 10.2337/diacare.26.3.770; http://care.diabetesjournals.org/content/26/3/770.full. ISSN: 0149-5992.
  88. Long-term effect of 3-week intravenous alpha-lipoic acid administration in symptomatic diabetic polyneutropathy with clinical manifestations. Ametov, A.S., et al., et al. 12, s.l.: Medicina, Moskva, RUSSIE, FEDERATION DE (1923) (Revue), 2010, Terapevtičeskij arhiv, Vol. 82, pp. 61-64. http://cat.inist.fr/?aModele=afficheN&cpsidt=23929839. ISSN: 0040-3660.
  89. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. McIlduff, Courtney E. and Rutkove, Seward B. [ed.] Garry Walsh. 7, Aberdeen: Dovepress, September 5, 2011, Therapeutics and Clinical Risk Management, Vol. 2011, pp. 377-385. DOI: 10.2147/TCRM.S11325; https://www.dovepress.com/critical-appraisal-of-the-use-of-alpha-lipoic-acid-th. eISSN: 1178-203X.
  90. a-Lipoic Acid in the Treatment of Diabetic Peripheral and Cardiac Autonomic Neuropathy. Ziegler, Dan and Gries, F. Arnold. [ed.] Gordon C. Weir. Suppl 2, Boston: American Diabetes Association, September 1997, Diabetes, Vol. 46, pp. S62-S66. DOI: 10.2337/diab.46.2.S62; http://diabetes.diabetesjournals.org/content/46/Supplement_2/S62. ISSN: 0012-1797.
  91. Treatment of Diabetic Sensory Polyneuropathy. Zilliox, Lindsay and Russell, James W. [ed.] William J. Weiner. 2, Baltimore: Springer Science+Business Media, LLC, April 1, 2011, Current Treatment Options in Neurology, Vol. 13, pp. 143-159. DOI: 10.1007/s11940-011-0113-1; http://link.springer.com/article/10.1007%2Fs11940-011-0113-1. ISSN: 1092-8480.
  92. Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy: The NATHAN 1 trial. Ziegler, Dan, et al., et al. [ed.] Vivian A. Fonseca. 9, Alexandria: American Diabetes Association, September 2011, Diabetes Care, Vol. 34, pp. 2054-2060. DOI: 10.2337/dc11-0503; http://care.diabetesjournals.org/content/34/9/2054. ISSN: 0149-5992.
  93. α-Lipoic Acid in Liver Metabolism and Disease. Bustamante, Juanita, et al., et al. [ed.] Kelvin J.A. Davies and William A. Pryor. 6, Los Angeles: Elsevier Science Inc., April 1998, Free Radical Biology & Medicine, Vol. 24, pp. 1023-1039. DOI: 10.1016/S0891-5849(97)00371-7; http://www.sciencedirect.com/science/article/pii/S0891584997003717. ISSN: 0891-5849.
  94. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Vinik, Aaron I. and Casellini, Carolina M. [ed.] Ming Zou. 6, Oklahoma City: Dove Medical Press Ltd, February 22, 2013, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol. 2013, pp. 57-78. DOI: 10.2147/DMSO.S24825; https://www.dovepress.com/guidelines-in-the-management-of-diabetic-nerve-pain-clinical-utility-o-peer-reviewed-article-DMSO. ISSN: 1178-7007.
  95. Alpha Lipoic Acid for Symptomatic Peripheral Neuropathy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Trials. Mijnhout, Gerritje S., et al., et al. [ed.] Stephen L. Atkin. Article ID 456279, New York: Hindawi Publishing Corporation, 2012, International Journal of Endocrinology, Vol. 2012, pp. 1-8. DOI: 10.1155/2012/456279; http://www.hindawi.com/journals/ije/2012/456279/. ISSN: 1687-8337.
  96. Lipoic acid effects on established atherosclerosis. Ying, Zhekang, et al., et al. [ed.] Bertil Fredholm and Frank Porreca. 3-4, Columbus: Elsevier Inc., January 16, 2010, Life Sciences, Vol. 86, pp. 95-102. DOI: 10.1016/j.lfs.2009.11.009; http://www.sciencedirect.com/science/article/pii/S0024320509004640. ISSN: 0024-3205.
  97. Oral Treatment With α-Lipoic Acid Improves Symptomatic Diabetic Polyneuropathy: The SYDNEY 2 trial. Ziegler, Dan, et al., et al. [ed.] Mayer B. Davidson. 11, Alexandria: American Diabetes Association, November 2006, Diabetes Care, Vol. 29, pp. 2365-2370. DOI: 10.2337/dc06-1216; http://care.diabetesjournals.org/content/29/11/2365. ISSN: 0149-5992.
  98. Switching from pathogenetic treatment with α-lipoic acid to gabapentin and other analgesics in painful diabetic neuropathy: a real-world study in outpatients. Ruessmann, Heinz-Jürgen. [ed.] Philip Raskin. 3, Dallas: Elsevier Inc., May-June 2009, Journal of Diabetes and Its Complications, Vol. 23, pp. 174-177. DOI: 10.1016/j.jdiacomp.2008.02.002; http://www.jdcjournal.com/article/S1056-8727(08)00024-X/abstract. ISSN: 1056-8727.
  99. Treatment for diabetic mononeuropathy with α-lipoic acid. Tankova, T., Cherninkova, S. and Koev, D. [ed.] Graham Jackson. 6, London: John Wiley & Sons, Inc., June 2005, International Journal of Clinical Practice, Vol. 59, pp. 645-650. http://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2005.00452.x/abstract; http://onlinelibrary.wiley.com/doi/10.1111/j.1742-1241.2005.00452.x/abstract. ISSN: 1368-5031.
  100. Effects of Alpha-Lipoic Acid on Body Weight in Obese Subjects. Koh, Eun Hee, et al., et al. [ed.] Joseph S. Alpert. 1, Tucson: Elsevier Inc., January 2011, The American Journal of Medicine, Vol. 124, pp. 85.e1-8. DOI: 10.1016/j.amjmed.2010.08.005; http://www.amjmed.com/article/S0002-9343(10)00743-6/abstract. ISSN: 0002-9343.
  101. Burning mouth syndrome: a review and update. Sun, Andy, et al., et al. [ed.] Erik Dabelsteen. 9, Copenhagen: John Wiley & Sons Ltd, October 2013, Journal of Oral Pathology & Medicine, Vol. 42, pp. 649-655. DOI: 10.1111/jop.12101; http://onlinelibrary.wiley.com/doi/10.1111/jop.12101/abstract. eISSN: 1600-0714.
  102. Interventions for the treatment of burning mouth syndrome. Zakrzewska, Joanna M, Forssell, Heli and Glenny, Anne-Marie. [ed.] Cochrane Oral Health Group. 1, s.l.: John Wiley & Sons, Ltd., January 24, 2005, Cochrane Database of Systematic Reviews, p. Art. No.: CD002779. DOI: 10.1002/14651858.CD002779.pub2; http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002779.pub2/abstract.
  103. Alpha lipoic acid efficacy in burning mouth syndrome. A controlled clinical trial. Palacios-Sánchez, Begoña, et al., et al. [ed.] Jose V. Bagan and Crispian Scully. 4, Valencia; London: Sociedad Española de Medicina Oral, Sociedad Española de Odontoestomatología para el Minusválido y Pacientes Especiales, Sociedad Española de Cirugía Bucal, Academia Iberoamericana de Patología y Medicinal Bucal, July 1, 2015, Medicina Oral Patologia Oral y Cirugia Bucal, Vol. 20, pp. e435-e440. DOI: 10.4317/medoral.20410; http://www.medicinaoral.com/pubmed/medoralv20_i4_p435.pdf. ISSN: 1698-4447.
  104. Burning mouth syndrome: Update. López-Jornet, Pia, et al., et al. [ed.] Jose V. Bagan and Crispian Scully. 4, Valencia; London: Sociedad Española de Medicina Oral, Sociedad Española de Odontoestomatología para el Minusválido y Pacientes Especiales, Sociedad Española de Cirugía Bucal, Academia Iberoamericana de Patología y Medicinal Bucal, July 2010, Medicina Oral Patologia Oral y Cirugia Bucal, Vol. 15, pp. 562-568. DOI: 10.4317/medoral.15.e562; http://www.medicinaoral.com/medoralfree01/v15i4/medoralv15i4p562.pdf. ISSN: 1698-4447.
  105. Alpha lipoic acid in burning mouth syndrome - a randomized double-blind placebo-controlled trial. Cavalcanti, Desirée Rosa and Da Silveira, Fernando Ricardo Xavier. [ed.] Erik Dabelsteen. 3, Copenhagen: John Wiley & Sons A/S, March 2009, Journal of Oral Pathology & Medicine, Vol. 38, pp. 254-261. DOI: 10.1111/j.1600-0714.2008.00735.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1600-0714.2008.00735.x/abstract. eISSN: 1600-0714.
  106. Burning mouth syndrome (BMS): double blind controlled study of alpha-lipoic acid (thioctic acid) therapy. Femiano, F. and Scully, C. [ed.] Erik Dabelsteen. 5, Copenhagen: John Wiley & Sons Ltd, May 2002, Journal of Oral Pathology & Medicine, Vol. 31, pp. 267-269. DOI: 10.1034/j.1600-0714.2002.310503.x; http://onlinelibrary.wiley.com/doi/10.1034/j.1600-0714.2002.310503.x/abstract. eISSN: 1600-0714.
  107. Efficacy of alpha lipoic acid in burning mouth syndrome: a randomized, placebo-treatment study. López-Jornet, P., Camacho-Alonso, F. and Leon-Espinosa, S. [ed.] Peter Svensson. 1, Aarhus: Blackwell Publishing Ltd, January 2009, Journal of Oral Rehabilitation, Vol. 36, pp. 52-57. DOI: 10.1111/j.1365-2842.2008.01914.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2842.2008.01914.x/abstract. eISSN: 1365-2842.
  108. Lack of efficacy of alpha-lipoic acid in burning mouth syndrome: A double-blind, randomized, placebo-controlled study. Carbone, Mario, et al., et al. [ed.] Herman O. Handwerker. 5, Erlangen: European Pain Federation, May 2009, European Journal of Pain, Vol. 13, pp. 492-496. DOI: 10.1016/j.ejpain.2008.06.004; http://onlinelibrary.wiley.com/doi/10.1016/j.ejpain.2008.06.004/abstract. eISSN: 1532-2149.
  109. Potentiation of Chemical Ototoxicity by Noise. Steyger, Peter S. [ed.] Catherine V. Palmer. 1, Pittsburgh: Thieme Medical Publishers, February 1, 2009, Seminars in Hearing, Vol. 30, pp. 38-46. DOI: 10.1055/s-0028-1111105; https://www.thieme-connect.de/DOI/DOI?10.1055/s-0028-1111105. ISSN: 0734-0451.
  110. Gratton, Michael Anne and Smyth, Brendan J. Ototoxicity of Platinum Compounds. [ed.] Peter S. Roland and John A. Rutka. Ototoxicity. Hamilton, Ontario: BC Decker Inc., 2004, 6, pp. 60-75. ISBN: 1-55009-263-4.
  111. Rotstein, Coleman and Mandell, Lionel. Clinical Aminoglycoside Ototoxicity. [ed.] Peter S. Roland and John A. Rutka. Ototoxicity. Hamilton: BC Decker Inc., 2004, 8, pp. 82-92. ISBN: 1-55009-263-4.
  112. Schacht, Jochen. Mechanisms for Aminoglycoside Ototoxicity: Basic Science Research. [ed.] Peter S. Roland and John A. Rutka. Ototoxicity. Hamilton, Ontario: BC Decker Inc., 2004, 9, pp. 93-100. ISBN: 1-55009-263-4.
  113. Aronson, Jeffrey K. Meyler's Side Effects of Antimicrobial Drugs. Amsterdam: Elsevier B.V., 2010. ISBN-13: 9780080932934.
  114. Water, Thomas R. Van De and Water, Thomas R. Van De. Ototoxic Damage to Hearing: Otoprotective Therapies. [ed.] Peter S. Roland and John A. Rutka. Ototoxicity. Hamilton: BC Decker Inc., 2004, 20, pp. 170-183. ISBN: 1-55009-263-4.
  115. Alpha-lipoic acid protects against cisplatin-induced ototoxicity via the regulation of MAPKs and proinflammatory cytokines. Kim, Jeongho, et al., et al. [ed.] Ernesto Carafoli. 2, Padua: Elsevier Inc., June 27, 2014, Biochemical and Biophysical Research Communications, Vol. 449, pp. 183-189. DOI: 10.1016/j.bbrc.2014.04.118; http://www.sciencedirect.com/science/article/pii/S0006291X14007815. ISSN: 0006-291X.
  116. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Guo, Ying, et al., et al. [ed.] Fred Ashbury. 5, Toronto: Springer-Verlag, May 2014, Supportive Care in Cancer, Vol. 22, pp. 1223-1231. DOI: 10.1007/s00520-013-2075-1; http://link.springer.com/article/10.1007%2Fs00520-013-2075-1. ISSN: 0941-4355.
  117. VA Office of Research and Development; Oregon Health and Science University. Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin. Portland: ClinicalTrials.gov, 2014. Study Record Detail. NCT00477607.
  118. Renzi, Lisa M. and Hammond, Billy R. Nutrition as a Mediator of Visual Health Across the Lifespan. [ed.] Klaus Kraemer. Sight and Life. Basel: Royal DSM, 2010, Vol. 2, pp. 2-11. ISBN: 978-3-906412-62-7.
  119. Abel Jr., Robert. Age-Related Macular Degeneration. [ed.] David Rakel. Integrative Medicine. 3rd. Philadelphia: Saunders: Elsevier Inc., 2012, 83, pp. 766-775. ISBN: 978-1-4377-1793-8.
  120. Senile Macular Degeneration and Alpha Lipoic Acid. Pavljašević, Suzana, Sefić-Kasumović, Sanja and Bejtić-Muhović, Jasna. [ed.] Midhat Jašić. 2, Tuzla: Faculty of Pharmacy, University of Tuzla and Food Technology, University of Osijek, December 2013, Food in Health and Disease, Vol. 2, pp. 63-70. ISSN: 2233-1220.
  121. Harris, Geoffrey R., Pratt, Steven G. and Richer, Stuart. Age-Related Macular Degeneration. [ed.] Ingrid Kohlstadt. Advancing Medicine with Food and Nutrients. 2nd. Boca Raton: CRC Press: Taylor & Francis Group, LLC, 2012, 1, pp. 3-30. ISBN: 978-1-4398-8772-1.
  122. Advances in pharmacological strategies for the prevention of cataract development. Gupta, S.K., et al., et al. [ed.] Barun K. Nayak. 3, Mumbai: All India Ophthalmological Society, May-June 2009, Indian Journal of Ophthalmology, Vol. 57, pp. 175-183. DOI: 10.4103/0301-4738.49390; http://www.ijo.in/article.asp?issn=0301-4738;year=2009;volume=57;issue=3;spage=175;epage=183;aulast=Gupta. ISSN: 0301-4738.
  123. Effect of the Administration of Alpha-Lipoic Acid on Contrast Sensitivity in Patients with Type 1 and Type 2 Diabetes. Gębka, Anna, Serkies-Minuth, Ewelina and Raczyńska, Dorota. [ed.] Katarzyna Zorena. Article ID 131538, Gdansk: Hindawi Publishing Corporation, February 10, 2014, Mediators of Inflammation, Vol. 2014, pp. 1-7. DOI: 10.1155/2014/131538; http://www.hindawi.com/journals/mi/2014/131538/. ISSN: 0962-9351.
  124. Comprehensive Review of the Effects of Diabetes on Ocular Health. Skarbez, Kathryn, et al., et al. 4, s.l.: Informa Plc, August 2010, Expert Review of Ophthalmology, Vol. 5, pp. 557-577. DOI: 10.1586/eop.10.44; http://informahealthcare.com/doi/abs/10.1586/eop.10.44. ISSN: 1746-9899.
  125. Effects of Nutritional Supplement with α-Lipoic Acid in Patients with Recurrent Pterygium. Godinez, Jorge Guillermo Hurtado, et al., et al. [ed.] Richard B. Rosen. 3, New York: OMICS Group, May 20, 2014, Journal of Clinical & Experimental Ophthalmology, Vol. 5, pp. 1-7. DOI: 10.4172/2155-9570.1000338; http://www.omicsonline.org/open-access/effects-of-nutritional-supplement-with-lipoic-acid-in-patients-with-recurrent-pterygium-2155-9570.1000338.php?aid=27305. ISSN: 2155-9570.
  126. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Heinisch, B.B. and Francesconi, M. [ed.] John P.A. Ioannidis. 2, Stanford: Stichting: European Society for Clinical Investigation Journal Foundation, February 2010, European Journal of Clinical Investigation, Vol. 40, pp. 148-154. DOI: 10.1111/j.1365-2362.2009.02236.x; http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2362.2009.02236.x/abstract. ISSN: 1365-2362.
  127. Houston, Mark C. Hypertension: Nutrition, Nutraceuticals, Vitamins, Antioxidants, and Minerals in Prevention and Treatment. [ed.] Ingrid Kohlstadt. Advancing Medicine with Food and Nutrients. Boca Raton: CRC Press: Taylor & Francis Group, LLC, 2012, 6, pp. 105-134. ISBN: 978-1-4398-8772-1.
  128. Abel, Jr., Robert. Cataracts. [ed.] David Rakel. Integrative Medicine. 3rd. Philadelphia: Saunders: Elsevier Inc., 2012, 82, pp. 758-765e2. ISBN: 978-1-4377-1793-8.
  129. α-Lipoic Acid Antioxidant Treatment Limits Glaucoma-Related Retinal Ganglion Cell Death and Dysfunction. Inman, Denise M., et al., et al. [ed.] Andreas Ohlmann. 6, Regensburg: Public Library of Science, June 5, 2013, PLoS ONE, Vol. 8, p. e65389. DOI: 10.1371/journal.pone.0065389; http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0065389. eISSN: 1932-6203.
  130. TGF-β(2)- and H(2)O(2)-induced biological changes in optic nerve head astrocytes are reduced by the antioxidant alpha-lipoic acid. Yu, A.L., Moriniere, J. and Welge-Lussen, U. [ed.] B. Corcóstegui, D.E. Pelayes and U. Pleyer. 3, Barcelona; Buenos Aires; Berlin: S. Karger AG, Basel, June 16, 2012, Ophthalmic Research, Vol. 48, pp. 156-164. DOI: 10.1159/000337835;http://www.karger.com/ProdukteDB/Produkte.asp?nr=000337835. ISSN: 0030-3747.
  131. Retinal Hemodynamic Effects of Antioxidant Supplementation in an Endotoxin-Induced Model of Oxidative Stress in Humans. Told, Reinhard, et al., et al. [ed.] David C. Beebe. 4, St. Louis: Association for Research in Vision and Ophthalmology, April 2014, Investigative Ophthalmology & Visual Science, Vol. 55, pp. 2220-2227. DOI: 10.1167/iovs.13-13784; http://iovs.arvojournals.org/article.aspx?articleid=2189724. eISSN: 1552-5783.
  132. Oxidative Stress: Implications for the Development of Diabetic Retinopathy and Antioxidant Therapeutic Perspectives. Wu, Ying, Tang, Luosheng and Chen, Baihua. [ed.] Ersin Fadillioglu. Article ID 752387, Malatya: Hindawi Publishing Corporation, August 14, 2014, Oxidative Medicine and Cellular Longevity, Vol. 2014, pp. 1-12. DOI: 10.1155/2014/752387; http://www.hindawi.com/journals/omcl/2014/752387/. ISSN: 1942-0900.
  133. Tarr, Joanna M., et al., et al. Retinopathy in Diabetes. [ed.] Shamim I. Ahmad. Diabetes: An Old Disease, a New Insight. Nottingham: Landes Bioscience and Springer Science+Business Media, 2012, Vols. Advances in Experimental Medicine and Biology, Vol. 771, 10, pp. 88-106. ISBN: 978-1-4614-5440-3.
  134. Antioxidants in the Prevention and Treatment of Diabetic Retinopathy - A Review. da Silva, Sara Baptista, et al., et al. [ed.] Charles W. Heilig and Rao M.Uppu. 3, Jacksonville; Baton Rouge: OMICS Group, December 2010, Journal of Diabetes & Metabolism, Vol. 1, pp. 1-10. DOI: 10.4172/2155-6156.1000111; http://www.omicsonline.org/2155-6156/2155-6156-1-111.digital/2155-6156-1-111.html. ISSN: 2155-6156.
  135. Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes. Du, X., Edelstein, D. and Brownlee, M. [ed.] Edwin Gale. 10, s.l.: Springer-Verlag: European Association for the Study of Diabetes, October 2008, Diabetologia, Vol. 51, pp. 1930-1932. Trial registration: NCT00703989; DOI: 10.1007/s00125-008-1100-2; http://link.springer.com/article/10.1007%2Fs00125-008-1100-2. ISSN: 0012-186X.
  136. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. Vidović, Bojana, et al., et al. [ed.] Miro Jakovljević and Werner Schöny. 3, Zagreb; Linz: Medicinska naklada, 2014, Psychiatria Danubina, Vol. 26, pp. 205-213. ISSN: 0353-5053.
  137. Alpha-Lipoic Acid for the Prevention of Diabetic Macular Edema. Haritoglou, C., et al., et al. [ed.] J. Cunha-Vaz. 3, Coimbra: S. Karger AG, Basel, September 2011, Ophthalmologica, Vol. 226, pp. 127-137. DOI: 10.1159/000329470; http://www.karger.com/OpenUrl/Index/000329470. ISSN: 0030-3755.
  138. Alpha-lipoic acid in the treatment of nonproliferative diabetic retinopathy. Demidova, Tatiana Yulevana and Trachtenberg, Yulia A. [ed.] Dedov Ivan Ivanovich. 4, Moscow: Russian Federation, December 2011, Diabetes Mellitus, Vol. 14, pp. 82-86. DOI: 10.14341/2072-0351-5823; http://endojournals.ru/index.php/dia/article/view/5823. ISSN: 2072-0351.
  139. Oxidative Stress in Preretinopathic Diabetes Subjects and Antioxidants. Nebbioso, Marcella, et al., et al. [ed.] Satish K. Garg. 3, Denver: Mary Ann Liebert, Inc., March 2012, Diabetes Technology & Therapeutics, Vol. 14, pp. 257-263. DOI: 10.1089/dia.2011.0172; http://online.liebertpub.com/doi/abs/10.1089/dia.2011.0172. ISSN: 1520-9156.
  140. Current Trends in Neuropathic Pain Treatments with Special Reference to Fibromyalgia. Offenbaecher, Martin and Ackenheil, Manfred. [ed.] Jack M. Gorman. 4, New York: MBL Communications Inc., April 2005, CNS Spectrums, Vol. 10, pp. 285-297. ISSN: 1092-8529.
  141. Clinical Symptoms in Fibromyalgia Are Better Associated to Lipid Peroxidation Levels in Blood Mononuclear Cells Rather than in Plasma. Cordero, Mario D., et al., et al. [ed.] Antoni L. Andreu. 10, Barcelona: Public Library of Science, October 28, 2011, PLoS ONE, Vol. 6, p. e26915. DOI: 10.1371/journal.pone.0026915; http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0026915. eISSN: 1932-6203.
  142. Comparison of shock wave therapy and nutraceutical composed of Echinacea angustifolia, alpha lipoic acid, conjugated linoleic acid and quercetin (perinerv) in patients with carpal tunnel syndrome. Notarnicola, Angela, et al., et al. [ed.] Pio Conti. 2, Chieti: SAGE Publications, June 2015, International Journal of Immunopathology and Pharmacology, Vol. 28, pp. 256-262. DOI: 10.1177/0394632015584501; http://iji.sagepub.com/content/28/2/256. ISSN: 0394-6320.
Disclaimer: This website is not intended to replace professional consultation, diagnosis, or treatment by a licensed physician. If you require any medical related advice, contact your physician promptly. Information presented on this website is exclusively of a general reference nature. Do not disregard medical advice or delay treatment as a result of accessing information at this site.